The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
AMG 509 (xaluritamig), an anti-STEAP1 XmAb 2+ 1 T-cell redirecting immune therapy with avidity-dependent activity against prostate cancer
O Nolan-Stevaux, C Li, L Liang, J Zhan, J Estrada… - Cancer Discovery, 2024 - AACR
The tumor-associated antigen STEAP1 is a potential therapeutic target that is expressed in
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
most prostate tumors and at increased levels in metastatic castration-resistant prostate …
Cancer therapy with antibodies
The greatest challenge in cancer therapy is to eradicate cancer cells with minimal damage
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
to normal cells. Targeted therapy has been developed to meet that challenge, showing a …
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
T Dorff, LG Horvath, K Autio, A Bernard-Tessier… - Clinical Cancer …, 2024 - AACR
Purpose: Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA)
x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic …
x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic …
A pivotal decade for bispecific antibodies?
M Surowka, C Klein - Mabs, 2024 - Taylor & Francis
Bispecific antibodies (bsAbs) are a class of antibodies that can mediate novel mechanisms
of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of …
of action compared to monospecific monoclonal antibodies (mAbs). Since the discovery of …
[HTML][HTML] Left out in the cold: moving beyond hormonal therapy for the treatment of immunologically cold prostate cancer with CAR T cell immunotherapies
Prostate cancer is primarily hormone-dependent, and medical treatments have focused on
inhibiting androgen biosynthesis or signaling through various approaches. Despite …
inhibiting androgen biosynthesis or signaling through various approaches. Despite …
T-Cell redirecting bispecific antibodies: a review of a novel class of immuno-oncology for advanced prostate cancer
J Palecki, A Bhasin, A Bernstein, PJ Mille… - Cancer Biology & …, 2024 - Taylor & Francis
Novel T-cell immunotherapies such as bispecific T-cell engagers (BiTEs) are emerging as
promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific …
promising therapeutic strategies for prostate cancer. BiTEs are engineered bispecific …
Clinical Applications of the Gut Microbiome in Genitourinary Cancers
CB Nguyen, UN Vaishampayan - American Society of Clinical …, 2024 - ascopubs.org
Recently recognized as one of the hallmarks of cancer, the microbiome consists of symbiotic
microorganisms that play pivotal roles in carcinogenesis, the tumor microenvironment, and …
microorganisms that play pivotal roles in carcinogenesis, the tumor microenvironment, and …
Bi-specific T-cell engagers (BiTEs) in prostate cancer and strategies to enhance development: hope for a BiTE-r future
H Lampe, L Tam, AR Hansen - Frontiers in Pharmacology, 2024 - frontiersin.org
Metastatic castrate resistant prostate cancer (mCRPC) continues to have poor survival rates
due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of …
due to limited treatment options. Bi-specific T cell engagers (BiTEs) are a promising class of …
Bispecific T-cell Engagers in Metastatic Castration-Resistant Prostate Cancer
To date, immune targeting agents have provided limited benefits in patients with metastatic
prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown …
prostate cancer. Bispecific T-cell engagers, especially targeting STEAP1, have shown …